Triomics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 55

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $22M

  • Investors
  • 12

Triomics General Information

Description

Developer of an interconnectivity and workflow automation platform intended to accelerate clinical trials. The company's platform eliminates the operational inefficiencies in data collection, patient recruitment, and other laborious tasks involved in clinical research, enabling pharmaceutical companies and contract research organizations to deliver rapid, cost-effective, optimal clinical trials.

Contact Information

Website
www.triomics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 355 Bryant Street
  • Unit 403
  • San Francisco, CA 94107
  • United States
+1 (888)
Primary Industry
Business/Productivity Software
Other Industries
Other Healthcare Technology Systems
Vertical(s)
Big Data, SaaS, Artificial Intelligence & Machine Learning, HealthTech, Life Sciences, Oncology
Corporate Office
  • 355 Bryant Street
  • Unit 403
  • San Francisco, CA 94107
  • United States
+1 (888)

Triomics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Triomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 27-May-2026 $22M Completed Generating Revenue
5. Accelerator/Incubator 02-Jul-2024 Completed Generating Revenue
4. Early Stage VC (Series A) 09-May-2024 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2024 Completed Generating Revenue
2. Accelerator/Incubator 01-Jan-2021 $125K $125K Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Triomics’s complete valuation and funding history, request access »

Triomics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A-5
Series A-4
Series A-3
Series A-2 990,565 $0.000010 $0.13 $0.13 1x $0.13 3.43%
Series A-1 5,135,579 $0.000010 $2.19 $2.19 1x $2.19 17.79%
To view Triomics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Triomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an interconnectivity and workflow automation platform intended to accelerate clinical trials. The company's
Business/Productivity Software
San Francisco, CA
55 As of 2025

Burlington, MA
 

Bellevue, WA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Triomics Competitors (23)

One of Triomics’s 23 competitors is Nuance Communications, a Formerly VC-backed company based in Burlington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nuance Communications Formerly VC-backed Burlington, MA
Edifecs Private Equity-Backed Bellevue, WA
TriNetX Private Equity-Backed Cambridge, MA
Definitive Healthcare Private Equity-Backed Framingham, MA
QuantHealth Venture Capital-Backed Tel Aviv, Israel
You’re viewing 5 of 23 competitors. Get the full list »

Triomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Triomics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Battery Ventures Growth/Expansion Minority
Oncology Ventures Venture Capital Minority
Texas Oncology Corporation Minority
PharmStars Accelerator/Incubator
General Catalyst Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

Triomics FAQs

  • When was Triomics founded?

    Triomics was founded in 2020.

  • Where is Triomics headquartered?

    Triomics is headquartered in San Francisco, CA.

  • What is the size of Triomics?

    Triomics has 55 total employees.

  • What industry is Triomics in?

    Triomics’s primary industry is Business/Productivity Software.

  • Is Triomics a private or public company?

    Triomics is a Private company.

  • What is the current valuation of Triomics?

    The current valuation of Triomics is .

  • What is Triomics’s current revenue?

    The current revenue for Triomics is .

  • How much funding has Triomics raised over time?

    Triomics has raised $37.1M.

  • Who are Triomics’s investors?

    Battery Ventures, Oncology Ventures, Texas Oncology, PharmStars, and General Catalyst are 5 of 12 investors who have invested in Triomics.

  • Who are Triomics’s competitors?

    Nuance Communications, Edifecs, TriNetX, Definitive Healthcare, and QuantHealth are some of the 23 competitors of Triomics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process